Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 3:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Restenoses, Coronary Clear all
Completed Phase 4 Interventional

Study of the Xience V Everolimus-eluting Stent in Saphenous Vein Graft Lesions

NCT00911976
View directory record Official record
Conditions
Coronary Artery Bypass, Atherosclerosis
Interventions
Xience V coronary stent
Device
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Sep 10, 2026, 3:25 PM EDT
Not listed No phase listed Observational

Intra-stent Tissue Evaluation Within BMS and DES > 3 Years Since Implantation

NCT01835301
View directory record Official record
Conditions
In-stent Coronary Artery Restenosis
Interventions
Not listed
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 10, 2026, 3:25 PM EDT
Completed Not applicable Interventional Results available

Absorb IV Randomized Controlled Trial

NCT02173379
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
98
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 10, 2026, 3:25 PM EDT
Completed Phase 3 Interventional

The SOS (Stenting Of Saphenous Vein Grafts) Trial

NCT00247208
View directory record Official record
Conditions
Coronary Artery Bypass, Arteriosclerosis
Interventions
Taxus polymer-based paclitaxel-eluting stent, Express 2 bare metal stent
Device
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
4
States / cities
Little Rock, Arkansas • Iowa City, Iowa • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2012 · Synced Sep 10, 2026, 3:25 PM EDT
Completed Phase 4 Interventional

SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents

NCT00714545
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Restenosis
Interventions
Intracoronary brachytherapy
Radiation
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 10, 2026, 3:25 PM EDT
Completed No phase listed Observational

The SCRIPPS DES REAL WORLD Registry

NCT00714623
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Restenosis, Coronary Thrombosis
Interventions
Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)
Device
Lead sponsor
Paul S Teirstein, MD
Other
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2012 · Synced Sep 10, 2026, 3:25 PM EDT
Completed Not applicable Interventional

STAR and Deferred Stenting Study

NCT05089864
View directory record Official record
Conditions
Coronary Occlusion, Coronary Stenosis, Coronary Restenosis
Interventions
Stent Placement Timing - Early, Stent Placement Timing - Late
Other
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 10, 2026, 3:25 PM EDT
Completed Phase 3 Interventional Results available

SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

NCT00307047
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
XIENCE V® Everolimus Eluting Coronary Stent, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
3,687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
65
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fairfax, California + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 10, 2026, 3:25 PM EDT
Completed Not applicable Interventional Results available

A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)

NCT01923740
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
XIENCE V EECSS, Absorb BVS System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 10, 2026, 3:25 PM EDT
Recruiting No phase listed Observational

Abbott Vascular Medical Device Registry

NCT04573660
View directory record Official record
Conditions
Acute Myocardial Infarction, Restenoses, Coronary, Coronary Artery Lesions, Venous Embolism, Arterial Embolism
Interventions
Coronary and peripheral stents, Pacing catheters, Vascular plugs, Measurement and imaging (FFR and OCT), Peripheral dilatation catheters, Coronary dilatation catheters, Coronary and peripheral guidewires, Vessel closure/compression devices, Vascular access introducers
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
3,784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
7
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 10, 2026, 3:25 PM EDT
Completed Phase 3 Interventional Results available

SPIRIT PRIME Clinical Trial

NCT00916370
View directory record Official record
Conditions
Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Core size Xience Prime, Xience Prime Long Lesion (LL)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
56
States / cities
Fairhope, Alabama • Scottsdale, Arizona • Sacramento, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 10, 2026, 3:25 PM EDT
Completed Not applicable Interventional Results available

EXCEL Clinical Trial

NCT01205776
View directory record Official record
Conditions
Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Percutaneous Coronary Intervention, CABG
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Sep 10, 2026, 3:25 PM EDT
Completed Not applicable Interventional Results available

ABSORB III Randomized Controlled Trial (RCT)

NCT01751906
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
190
States / cities
Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 145 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 10, 2026, 3:25 PM EDT
Withdrawn No phase listed Observational

REWARDS- In-stent Restenosis

NCT03008772
View directory record Official record
Conditions
In-Stent Coronary Artery Restenosis
Interventions
Not listed
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 10, 2026, 3:25 PM EDT
Active, not recruiting Not applicable Interventional

SELUTION SLR™ 014 In-stent Restenosis

NCT04280029
View directory record Official record
Conditions
Coronary Restenosis
Interventions
SELUTION SLR 014 DEB, Standard of Care
Device
Lead sponsor
M.A. Med Alliance S.A.
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
34
States / cities
Loma Linda, California • Los Angeles, California • Torrance, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 10, 2026, 3:25 PM EDT
Completed No phase listed Observational

Whole Genome Association Study to Identify and Validate Genes for Restenosis: CardioGene Validation Proposal

NCT00589810
View directory record Official record
Conditions
Coronary Restenosis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
761 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 10, 2026, 3:25 PM EDT
Completed Phase 3 Interventional Results available

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

NCT00180479
View directory record Official record
Conditions
Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Sep 10, 2026, 3:25 PM EDT
Completed Phase 4 Interventional

Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)

NCT00963781
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Thrombosis
Interventions
Medtronic Endeavor Stent, Reduced duration (6 months) DAPT
Device · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 10, 2026, 3:25 PM EDT
Completed Phase 2Phase 3 Interventional

A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.

NCT00055510
View directory record Official record
Conditions
Graft Occlusion, Vascular, Coronary Restenosis, Atherosclerosis
Interventions
BO-653
Drug
Lead sponsor
Chugai Pharma USA
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
29
States / cities
Phoenix, Arizona • Tucson, Arizona • Burlingame, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 10, 2026, 3:25 PM EDT
Completed No phase listed Observational Results available

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)

NCT01120379
View directory record Official record
Conditions
Chronic Coronary Occlusion, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® EECSS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
5,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Sep 10, 2026, 3:25 PM EDT
Completed No phase listed Observational Results available

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)

NCT00676520
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
XIENCE V® Everolimus Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
8,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Sep 10, 2026, 3:25 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries

NCT00140101
View directory record Official record
Conditions
Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
ZoMaxx™ Drug-Eluting Coronary Stent System, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
74
States / cities
Huntsville, Alabama • Gilbert, Arizona • La Jolla, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2012 · Synced Sep 10, 2026, 3:25 PM EDT
Completed Phase 2Phase 3 Interventional

Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis

NCT00287573
View directory record Official record
Conditions
Coronary Restenosis
Interventions
TAXUS Express2, Brachytherapy (beta source)
Device · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2010 · Synced Sep 10, 2026, 3:25 PM EDT
Completed Phase 4 Interventional Results available

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

NCT01106534
View directory record Official record
Conditions
Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
placebo + aspirin, clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
Drug · Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
144
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 10, 2026, 3:25 PM EDT